Experimental validation of 5 in-silico predicted glioma biomarkers

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1625-1634

  Towner, Rheal A ^a,b   Jensen, Randy L ^d   Vaillant, Brian ^e   Colman, Howard ^d   Saunders, Debra ^a   Giles, Cory B ^a   Wren, Jonathan D ^a,c  

^a Cardiovascular Biology Research Program   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Oklahoma University Health Sciences Center   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e Seton Brain and Spine Institute   (United States)

Author keywords

Biomarkers; Gene databases; Glioblastoma multiforme; Gliomas; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; FIBULIN 1; LINGO 1; PLEXIN B2; SLIT 3; SPONDIN 1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; GENE EXPRESSION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC);

BIOMARKERS; GENE DATABASES; GLIOBLASTOMA MULTIFORME; GLIOMAS; IMMUNOHISTOCHEMISTRY;

ALGORITHMS; BRAIN; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MEMBRANE PROTEINS; NEOPLASM GRADING; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891884832     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not124     Document Type: Article

References (60)

1. Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Hinsdale, IL: Author; 2011. http://www.cbtrus.org/2011- NPCR-SEER/WEB-0407-Report-3-3-2011.pdf Accessed 17 July, 2013.
2. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117.
3. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
4. Riemenschneider MJ, JeukenJW,Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010;120(5): 567-584.
5. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010; 9(7):717-726.
6. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010;12(1):49-57.
7. Farias-Eisner G, BankAM,HwangBY, et al. Glioblastoma biomarkers from bench to bedside: Advances and challenges. Br J Neurosurg. 2012;26(2): 189-194.
8. Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine- DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta. 2012;1826(1):71-82.
9. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics. 2010;73(10):1823-1838.
10. Wren JD. A global meta-analysis of microarray expression data to predict unknown gene functions and estimate the literature-data divide. Bioinformatics. 2009;25(13):1694-1701.
11. DozmorovMG, Wren JD. High-throughput processing and normalization of one-color microarrays for transcriptional meta-analyses. BMC Bioinformatics. 2011;12(Suppl 10):S2.
12. DozmorovMG,Giles CB,WrenJD. Predicting gene ontology froma global meta-analysis of 1-color microarray experiments. BMC Bioinformatics. 2011;12(Suppl 10):S14.
13. Daum JR, Wren JD, Daniel JJ, et al. Ska3 is required for spindle checkpoint silencing and the maintenance of chromosome cohesion in mitosis. Curr Biol. 2009;19(17):1467-1472.
14. LupuC,ZhuH,PopescuNI,WrenJD,LupuF.NovelproteinADTRPregulates TFPI expression and function inhuman endothelial cells in normal conditions and in response to androgen. Blood. 2011;118(16):4463-4471.
15. Clemmensen SN, Bohr CT, Rorvig S, et al. Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol. 2012;91(3):495-500.
16. Towner RA, Jensen RL, Colman H, et al. ELTD1, a potential newbiomarker for gliomas. Neurosurgery. 2013; In press.
17. Wren JD, Garner HR. Shared relationship analysis: Ranking set cohesion and commonalities within a literature-derived relationship network. Bioinformatics. 2004;20(2):191-198.
18. Wren JD. Extending the mutual information measure to rank inferred literature relationships. BMC Bioinformatics. 2004;5:145.
19. Goel R, Muthusamy B, Pandey A, Prasad TS. Human Protein Reference Database and human proteinpedia as discovery resources for molecular biotechnology. Mol Biotechnol. 2011;48(1):87-95.
20. Giles CB, Wren JD. Large-scale directional relationship extraction and resolution. BMC Bioinformatics. 2008;9(Suppl 9):S11.
21. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009; 92(3):317-335.
22. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
23. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
24. Keshava Prasad TS,Goel R, Kandasamy K, et al. Human Protein Reference Database - 2009 update. Nucleic Acids Res. 2009;37(database issue):D767-72.
25. Ulrich TA, de Juan Pardo EM, Kumar S. The mechanical regidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res. 2009;69(10):4167-74.
26. Veeravalli KK, Rao JS. MMP-9 and uPAR regulated glioma cell migration. Cell Adh Migr. 2012;6(6):509-12.
27. Chetty C, Vanamala SK, Gondi CS, et al. MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal. 2012;24(2):549-59.
28. Wick W, Platten M, Weller M. Glioma cell invasion: Regulation of metalloproteinase activity by TGF-β. J Neuro-Oncol. 2001;53: 177-185.
29. Fowler A, Thomson D, Giles K, et al. miR-124a is frequently downregulated in glioblastoma and is involved in migration and invasion. Eur J Cancer. 2011;47(6):953-63.
30. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12(3):197-209.
31. Collen A, Hanemaaijer R, Lupu F, Quax PH, et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood. 2003;101(5):1810-7.
32. Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5): 1032-1042.
33. Gillespie DL, Flynn JR, Ragel BT, et al. Silencing of HIF-1alpha by RNA interference in human glioma cells in vitro and in vivo. Methods Mol Biol. 2009;487:283-301.
34. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL. Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev. 2007;30(3):181-187; discussion 187.
35. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 2007;13(8): 2441-2448.
36. Rong Y, Hu F, Huang R, et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006;66(14):7067-7074.
37. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus. 2006;20(4):E24.
38. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol. 2006;78(3):233-247.
39. Dickinson RE, Dallol A, Bieche I, et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer. 2004;91(12): 2071-2078
40. Davidson B, Stavnes HT, Holth A, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2011;15(3):535-544.
41. Gyorffy B, Dietel M, Fekete T, Lage H. A snapshot of microarraygenerated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer. 2008;18(6):1215-1233.
42. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5(12):e232.
43. Pyle-Chenault RA, Stolk JA, Molesh DA, et al. VSGP/F-spondin: A new ovarian cancer marker. Tumour Biol. 2005;26(5):245-257.
44. Lin ZY, Chuang WL. Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother. 2012;66(6):454-458.
45. Cheng YY, Jin H, Liu X, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer. 2008;99(12): 2083-2087.
46. Pupa SM, Argraves WS, Forti S, et al. Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene. 2004;23(12):2153-2160.
47. Wen Y, Giardina SF, Hamming D, et al. GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clin Cancer Res. 2006;12(20 Pt 1):5951-5959.
48. Wlazlinski A, Engers R, Hoffmann MJ, et al. Downregulation of several fibulin genes in prostate cancer. Prostate. 2007;67(16):1770-1780.
49. Kanda M, Nomoto S, Okamura Y, et al. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 2011;50(8):571-579.
50. Medioni C, Bertrand N, Mesbah K, et al. Expression of Slit and Robo genes in the developing mouse heart. Dev Dyn. 2010;239(12):3303-3311.
51. Katoh Y, Katoh M. Comparative genomics on SLIT1, SLIT2, and SLIT3 orthologs. Onco. Rep. 2005;14(5):1351-1355.
52. Holl EK, Roney KE, Allen IC, et al. Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. PLoS One. 2012;7(8): e43333.
53. Roney KE, O'Connor BP,Wen H, et al. Plexin-B2 negatively egulatesmacrophagemotility, Rac,andCdc42activation.PLoSOne.2011;6(9):e24795.
54. Argast GM, Croy CH, Couts KL, et al. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene. 2009;28(30):2697-2709.
55. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene. 2004;23(30):5131-5137.
56. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 2004;64(15):5212-5224.
57. Zhang Z,Xu X,Zhang Y,Zhou J,YuZ,He C.LINGO-1interacts withWNK1 to regulate nogo-induced inhibition of neurite extension. J Biol Chem. 2009;284(23):15717-15728.
58. Loov C, Fernqvist M, Walmsley A, Marklund N, Erlandsson A. Neutralization of LINGO-1 during in vitro differentiation of neural stem cells results in proliferation of immature neurons. PLoS One. 2012;7(1):e29771.
59. Stein T, Walmsley AR. The leucine-rich repeats of LINGO-1 are not required for self-interaction or interaction with the amyloid precursor protein. Neurosci Lett. 2012;509(1):9-12.
60. Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519-529.